Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.51 |
| ▸ | CTSG | P08311 | 5/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.50 |
| ▸ | IAPP | P10997 | 4/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28161120 | 0.90 | ELANE (0.53) | ELANECTSGGABRA1GABRB2IAPP | |
| SCHEMBL674691 | 0.88 | GABRA1 (0.64) | ELANECTSGGABRA1GABRB2IAPP | |
| SCHEMBL8379462 | 0.87 | ALDH1A1 (0.45) | ELANECTSGGABRA1GABRB2IAPP | |
| SCHEMBL2467818 | 0.87 | ALOX5 (0.56) | ELANECTSGGABRA1GABRB2IAPP | |
| SCHEMBL11611357 | 0.86 | PDCD1 (0.50) | ELANECTSGGABRA1GABRB2IAPP | |
| SCHEMBL31376379 | 0.86 | GABRA1 (0.61) | ELANECTSGGABRA1GABRB2IAPP | |
| SCHEMBL10523840 | 0.85 | ALOX5 (0.64) | ELANECTSGIAPPALOX5PTGS2 | |
| SCHEMBL5588855 | 0.82 | ELANE (0.49) | ELANECTSGGABRA1GABRB2IAPP | |
| SCHEMBL68921 | 0.82 | IAPP (0.65) | ELANECTSGGABRA1GABRB2IAPP | |
| SCHEMBL1005366 | 0.82 | GABRA1 (0.77) | ELANECTSGGABRA1GABRB2IAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948220-B1 | PROCESSES FOR MAKING MAGNOLOL DERIVATIVES | COLGATE PALMOLIVE CO (US) | 2018-07-04 | — | — | EP | claimed |
| US-9676690-B2 | Processes for making magnolol derivatives | COLGATE-PALMOLIVE COMPANY (US) | 2017-06-13 | — | — | US | claimed |
| US-20150361017-A1 | Processes for Making Magnolol Derivatives | COLGATE-PALMOLIVE COMPANY (US) | 2015-12-17 | — | — | US | claimed |
| EP-2948220-A1 | PROCESSES FOR MAKING MAGNOLOL DERIVATIVES | Colgate-Palmolive Company (US) | 2015-12-02 | — | — | EP | claimed |
| EP-2794535-A1 | PROCESSES FOR MAKING MAGNOLOL ANALOGS | Colgate-Palmolive Company (US) | 2014-10-29 | — | — | EP | claimed |
| WO-2014115156-A1 | PROCESSES FOR MAKING MAGNOLOL DERIVATIVES | COLGATE-PALMOLIVE COMPANY (US) | 2014-07-31 | — | — | WO | claimed |
| WO-2013095364-A1 | PROCESSES FOR MAKING MAGNOLOL ANALOGS | COLGATE-PALMOLIVE COMPANY (US) | 2013-06-27 | — | — | WO | claimed |
| CN-111356434-B | Composition comprising an oil and a polyion complex comprising a cellulose-based cationic polymer having at least one fatty chain | 莱雅公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116617116-A | Combination of polyion complex particles and non-polymeric acids having two or more acid dissociation constants | 莱雅公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230149958-A1 | DEVICE FOR SUPPLYING A COMPOSITION TO A PRESSURIZED DEPOSITION SYSTEM | JOHNSON & JOHNSON CONSUMER INC. (US) | 2023-05-18 | — | — | US | disclosed |
| CN-115484924-A | Hyaluronic acid production promoter and collagen production promoter | 株式会社资生堂 | 2022-12-16 | — | — | CN | disclosed |
| CN-108367175-B | Combination of polyion composite particles and hydrophilic or water-soluble UV filters | 莱雅公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-111356434-A | Composition comprising an oil and a polyionic complex comprising a cellulose-based cationic polymer having at least one fatty chain | 莱雅公司 | 2020-06-30 | — | — | CN | disclosed |
| EP-2605835-A2 | COMPOSITIONS COMPRISING PAULOWNIN AND/OR PAULOWNIA EXTRACTS AND USES THEREOF | Johnson & Johnson Consumer Companies Inc. (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2605749-A2 | COMPOSITIONS COMPRISING PAULOWNIN AND/OR PAULOWNIA EXTRACTS AND USES THEREOF | Johnson & Johnson Consumer Companies Inc. (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2013036229-A1 | ORAL AND SKIN CARE COMPOSITIONS BASED ON A 3, 3 ' - DIALKYL - 1, 1 ' - BIPHENYL - 2, 2 ' - DIOL OR A 3, 3 ' -DIALKENYL- 1, 1 ' -BIPHENYL- 2, 2 ' -DIOL | COLGATE-PALMOLIVE COMPANY (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2012024399-A2 | COMPOSITIONS COMPRISING PAULOWNIN AND/OR PAULOWNIA EXTRACTS AND USES THEREOF | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024392-A2 | COMPOSITIONS COMPRISING PAULOWNIN AND/OR PAULOWNIA EXTRACTS AND USES THEREOF | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024395-A2 | COMPOSITIONS COMPRISING PAULWNIN AND/OR PAULOWNIA EXTRACTS AND USES THEREOF | JOHNSON & JOHNSON CONSUMER COMPANIES INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024394-A2 | COMPOSITIONS COMPRISING PAULOWNIN AND/OR PAULOWNIA EXTRACTS AND USES THEREOF | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361017-A1 | Processes for Making Magnolol Derivatives | CYP4A11, CYP11B1, CYP3A4 | ELANE 4428/4885CTSG 3526/4885GABRA1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.